Market News

Emera (TSX:EMA) expect to deliver 2026 adjusted EPS growth above its annual target range of 5%-7%, while maintaining its target of 5%-7% annual adjust...

BTIG analyst Jake Fuller maintains Compass (NYSE:COMP) with a Buy and lowers the price target from $15 to $13.

Policy shifts rattled wound care sales, but sequential growth hints at stabilization.

Full capacity returns, but Q4 pricing faces a sizable headwind.

PCTY combines strong growth, high profitability, low debt and a bull flag with pocket pivot, making it a technically confirmed growth-screen candidate...

Susquehanna analyst Bascome Majors maintains GXO Logistics (NYSE:GXO) with a Positive and raises the price target from $60 to $66.

TSMC stock rose nearly 7% premarket after Taiwan tightened short-selling rules and readied a $15 billion fund to stem a semiconductor selloff.

For months, investors have been worrying about a long list of risks to the gravy train of artificial intelligence spending.

IREN Limited remains a Sell as dilution and debt risks grow despite AI cloud revenue gains. Click here for this IREN stock update.

Susquehanna analyst James Friedman maintains Genpact (NYSE:G) with a Neutral and raises the price target from $40 to $42.

Union Pacific reported strong Q3 2026 results, with revenue and EPS up 15%, but underlying freight revenue growth was only 6%. Read why UNP stock is a...

https://www.sec.gov/Archives/edgar/data/1920406/000095010326017073/dp256456_424b3-sata.htm

Susquehanna analyst James Friedman maintains Shift4 Payments (NYSE:FOUR) with a Positive and lowers the price target from $63 to $56.

Bloomin' Brands stock fell Friday despite topping Q3 estimates. Weak traffic and a soft Q4 outlook weighed on investor sentiment.

Scotiabank analyst John Zamparo downgrades Gildan Activewear (NYSE:GIL) from Sector Outperform to Sector Perform and lowers the price target from $...

ARS Pharma missed Q3 earnings and sales estimates; shares rose 5.6% premarket as analysts cut price targets despite neffy progress.

Needham analyst David Saxon maintains Globus Medical (NYSE:GMED) with a Buy and lowers the price target from $117 to $100.

Susquehanna analyst Shyam Patil maintains Expedia Group (NASDAQ:EXPE) with a Neutral and lowers the price target from $315 to $310.